Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

PLEASANTON, CA—Alan Mateo, a director at 10x Genomics, Inc. (NASDAQ:TXG), has recently increased his stake in the company.... In a turbulent market environment, 10X Genomics Inc (NASDAQ:TXG) ...

Investing.com - 10X Genomics (NASDAQ: TXG) reported second quarter EPS of $-0.53, $0.13 worse than the analyst estimate of $-0.40.